# A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants

> **NCT05885451** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 18 (actual)

## Conditions studied

- Chronic Graft-versus-Host Disease (cGVHD)

## Interventions

- **DRUG:** AMG 592
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05885451
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-29
- **Primary completion:** 2019-04-11
- **Final completion:** 2019-04-11
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05885451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05885451, "A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05885451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*